TargetMol

Ganoderic acid C1

Product Code:
 
TAR-TN1660
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN1660-1mg1mg£159.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1660-5mg5mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
Ganoderic acid C1 has anti-inflammatory activity, has potential for treating TNF-α? mediated inflammation in asthma and other inflammatory diseases. Ganoderic acid C1 has anti-tumor-promoting activity. It is moderately active inhibitors against HIV-1 protease.
CAS:
95311-97-0
Formula:
C30H42O7
Molecular Weight:
514.659
Pathway:
Neuroscience; DNA Damage/DNA Repair; Cell Cycle/Checkpoint; MAPK; NF-κb; Microbiology/Virology; Proteases/Proteasome; Immunology/Inflammation; Apoptosis
Purity:
0.98
SMILES:
[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](CC(=O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C
Target:
IL Receptor; TNF; NF-κB; MAPK; COX; HIV Protease; DNA/RNA Synthesis

References

Liu C, et al. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn's Disease Associated with Downregulation of NF-?B Signaling. Inflamm Bowel Dis. 2015 Aug;21(8):1918-25. Changda Liu, et al. Ganoderic acid C1 isolated from the anti-asthma formula, ASHMI? suppresses TNF-? production by mouse macrophages and peripheral blood mononuclear cells from asthma patients. Int Immunopharmacol. 2015 Aug;27(2):224-31.